DaVita Inc. (DVA) Earnings Call Transcript & Summary
May 12, 2025
Earnings Call Speaker Segments
Nic Eliason
executiveThanks for joining us on this initial quarterly earnings call. I am Nic Eliason, serving as Group Vice President of Investor Relations. With me here are Javier Rodriguez, who is our CEO, and Joel Ackerman, our CFO. I want to point out that on this call, forward-looking statements will be made as defined under the federal securities laws. Known and unknown risks and uncertainties apply to each of these statements, and those factors might lead to actual results differing materially from what the forward-looking statements describe. If you want more information about such risks and uncertainties, we direct you to the earnings press release for the first quarter along with our filings with the SEC, which include the latest annual report on Form 10-K, every later quarterly report on Form 10-Q, and additional filings we subsequently submit to the SEC. The forward-looking statements we make rest on information available to us at present, and we have no intention, and take on no obligation, to revise those statements unless the law demands it. Also, a reminder that certain non-GAAP financial measures will be covered on this call. You can find a reconciliation between these non-GAAP measures and the closest comparable GAAP financial measures in the earnings press release we furnished to the SEC, which is also posted on our website. At this point, I hand the call over to Javier Rodriguez.
Javier Rodriguez
executiveThank you, Nic, and I appreciate everyone being on today's call. As we wrap up the first quarter and think back on what has happened over these last several weeks, one thing stands out once more: our caregivers' resilience and commitment came through with every fresh obstacle. Right now, we are working to resolve a cybersecurity event that has interrupted certain parts of how we operate. Even with those difficulties, we hold firm. We keep providing care that sustains life, building a meaningful career path for our teammates and delivering value back to our shareholders. Today, I'll cover details about the cyber incident, walk through our results for the first quarter, talk about important policy updates and finish with what we expect for the rest of the year. First, as we always do, we'll start with the clinical highlights, which are the real bedrock of all that we do. In the past year, we started a community-focused effort alongside the YMCA aimed at educating people about chronic kidney disease and preventing it. Via this collaborative community kidney health program, YMCA sites across the country are helping deliver essential education, screenings for prechronic disease and vital kidney health resources straight to the communities with the greatest need. What we've seen so far is striking. In our first pilot, 30% of those screened turned out to have CKD that had gone undiagnosed before, opening up strong chances for early intervention and care that changes lives. Catching things early and educating people form the foundation of preventing kidney disease, and with this collaboration, we've set ambitious targets for reaching thousands of individuals, giving communities the knowledge required to narrow the gap in awareness around kidney health. Working with the YMCA is not merely a program. It shows our steadfast dedication to creating a healthier, stronger tomorrow. Before I turn to how we performed in the first quarter, I want to speak about the cybersecurity incident we made public last month. On April 12, we spotted a cybersecurity incident and quickly started responding to it; it encrypted portions of our system and impacted our operations. Though it is deeply distressing that bad actors keep targeting the health care community, this incident brought to light our team's steadfast dedication to patient care. I'm thankful to say that we delivered dialysis care without interruption for our patients on the day we found the incident and every day after at every one of our centers around the world. Because of how incredibly responsive our teams were and what we've invested in IT infrastructure, we have managed to restore both functions as of today. All the key platforms that our patients, doctors, and team members depend on — the lab and billing included — are up and running. For the remaining applications, we'll keep working on them in the weeks ahead. While restoring our systems is nearly complete, we'll need to address certain regulatory and legal steps as we work out the scope and character of the data that was taken, and send out any required notifications. We expect the bulk of expenses related to this incident to be one-time charges recorded in Q2, and our current estimate of the financial effects is built into the guidance we're giving today. Turning to how we did in the first quarter, adjusted operating income along with adjusted earnings per share both landed a bit above what we had anticipated. Broadly speaking, the drivers were better-than-expected results in patient care costs, phosphate binders, and our international business. That favorability was partly offset by a modest shortfall in treatment volume, which was in part caused by an unusually severe flu season. Let me give a bit more detail on phosphate binders, since they helped produce positive results this quarter. As a reminder, phosphate binders are oral medications that physicians prescribe so dialysis patients can avoid mineral bone disease. Starting this year, CMS moves phosphate binders out of Medicare Part D and into the dialysis benefit. Vita dispenses these drugs according to physician orders and gets reimbursed by CMS and Medicare Advantage plans on a per-script basis during the initial TDAPA period. Just as we anticipated last quarter, the biggest source of variability would come from drug mix, where prescriptions for iron-based binders have run above what we expected. That's a win for our patients, who are getting the medication that works best for their own clinical needs. We are still early in this transition and anticipate more variability as the year goes on. Even so, now that we have early data on the drug mix, we anticipate that phosphate binders will contribute full-year operating income at the top of the 0 to positive $50 million range we guided to previously. One more item about the first quarter, this one regarding capital allocation. Placing our available capital into innovation and high-return growth opportunities remains the priority — our recent Latin America acquisition is a good example. Past those opportunities, we remain dedicated to returning capital to shareholders through share repurchases. Roughly $680 million of stock has been repurchased since our last earnings call, a faster pace than usual for this period. Looking ahead to 2025, our buyback activity should be weighted toward the earlier part of the year, with a slower pace across the remaining months. Let me be clear: nothing about how we allocate capital has shifted. Switching gears now, I want to offer a few reflections on the incoming administration and what policy shifts might come with it. Things are developing fast, but one thing stays the same at the top of our list — standing up for the people we serve in statehouses and in Washington. Today I'm going to talk about three policy areas that touch the wider health care sector: tariffs, Medicaid, and enhanced premium tax credits. With regard to the first two, the policy remains in flux in both cases and there is still much to be learned, but at this point we don't see tariffs or Medicaid reform having any material financial effect. When it comes to qualified health plans and enhanced premium tax credits, we've said before that the cumulative operating income impact comes to $75 million to $120 million. That figure covers 3 years and presumes the enhanced premium tax credits expire entirely. Our view remains that this is the most probable range of outcomes. Like we said, exchange plan enrollment for 2025 came in strong during open enrollment, which suggests we'll likely land near the top end of that range. It's lucky for us that the policy shifts made recently have had only a small impact, but we remain vigilant and committed to being fierce advocates for patients. Turning to what lies ahead, we're keeping the 2025 guidance figures for adjusted operating income and adjusted earnings per share exactly where we set them three months ago. The cyber incident did generate certain challenges, but given how well we performed operationally in the first quarter, we're in a solid spot to achieve our full-year financial targets. With that, I'll pass it to Joel, who will walk through our financial results and expectations in more depth.
Joel Ackerman
executiveThanks, Javier. For the first quarter, adjusted operating income came in at $439 million. Adjusted EPS stood at $2, while free cash flow was negative $45 million. Our adjusted operating income exceeded the guidance provided last quarter, driven primarily by disciplined cost control, profitability from orals in the bundle landing at the top end of our range, and robust international results, partly offset by treatments that fell short of expectations. I'll begin with the specifics underlying our Q1 operating income results, then move to an update on 2025 guidance. U.S. treatments per day dropped 40 basis points compared with the first quarter of 2024 and landed roughly 50 basis points under our forecast. The main reason for the weakness was a higher rate of missed treatments, which resulted from a particularly bad flu season and a bigger impact than we expected from storms in January and February. Another factor adding to that shortfall was the negative effect on census tied to flu deaths, which exceeded our forecast for the quarter. Admissions growth stayed strong across the quarter, and that supports our view that the decline in admissions growth seen in the fourth quarter was just normal variation, not a trend. Looking ahead to the remainder of the year, the flu-related census impact from the first quarter will cause treatment volume for the rest of the year to be lower than we had expected before. On top of that, we believe the cybersecurity event that Javier walked us through resulted in unusually low patient admissions across about a two-week stretch during April. When you put those two elements together with the treatment volume we fell short on in Q1, our current expectation is a roughly 50 basis point drop in treatments for the full year. Keep in mind as well that our 2025 volume faces a drag from the PD supply constraint we ran into during the fourth quarter of 2024. Even with these near-term headwinds, we continue to believe we will get back to 2% volume growth, even if pinpointing when that happens is difficult. Just as we have said in prior guidance, these projections relate to the total number of treatments, rather than treatments delivered each day or non-acquired growth. Revenue per treatment was up by $4 during the quarter. Roughly ten dollars of that gain comes from fresh reimbursement tied to phosphate binders, while about five dollars of slippage stems from the usual first-quarter pattern of patients shouldering co-pays and deductibles. Sequentially, the cost of caring for each patient per treatment climbed seven dollars. The lift came mostly from around eight dollars per treatment in added expenses linked to phosphate binders, partly canceled out by a drop from the seasonally peak fourth quarter. On a sequential basis, first-quarter G&A expenses dropped thirty-three million dollars, once more reflecting a pullback from the typically inflated spending seen late in the year. Compared with the fourth quarter, adjusted international OI gained twenty-nine million dollars. Before we go further, keep in mind that Q4 took a hit from a $19 million reserve we set aside for older receivables in Brazil. Our value-based care arm, Integrated Kidney Care, posted $29 million in operating losses for the quarter, which matched what we had anticipated. Worth noting, IKC typically delivers stronger operating results during the back half of the year. In Q4, we moved the operations associated with a single IT product out of the IKC segment and over to U.S. other ancillary; this shifted approximately $4 million of operating loss away from IKC and into U.S. other ancillary results for that period. Looking at the full year, we anticipate this shift will carry an impact of roughly $17 million. Under the OI line, we recorded $18 million in other loss, primarily tied to Mozarc, the joint investment we hold with Medtronic. For the rest of the year, we anticipate this will be a steady quarterly run rate. During Q1, 3.7 million shares were bought back, and since the quarter closed, we have repurchased another 1.7 million shares. Our buyback activity keeps being guided by how we normally evaluate leverage ratio, liquidity and market price against what we see as intrinsic value. That quicker buying pace pushed our leverage level to 3.27x at quarter end, which sits close to the midpoint of our target leverage range. Debt expense for Q1 came in at $135 million. Starting in Q2, we expect debt expense to rise to about $145 million each quarter through the rest of the year. Now I'll move to what we expect for the full year 2025; we are reaffirming our guidance for full year adjusted operating income and earnings per share. Even with the difficulties from a tough flu season in Q1 and the headwinds we expect from the recent cyber incident, the fundamental strength of how our business performed in Q1, plus our higher forecast for orals profitability in the bundle, leaves us confident in our full year guidance. That wraps up my prepared remarks today. Operator, please open the call for Q&A.
Andrew Mok
analystI really appreciate all the detail you gave us regarding the cyber attack and treatment growth. When we turn to that 50-basis-point adjustment for the entire year, could you walk us through what portion came from flu during the first quarter? And what portion came from the cyber attack? Then, in the same way, how did flu affect us in the quarter? Could you break that down for us?
Joel Ackerman
executiveOf course, Andrew. Let's begin with the full year. Flu delivered the largest hit to the full year, though that's not driven by the first quarter — rather, it's a census decline during the first quarter that carries into the full year. So that accounts for slightly over half of the 50 basis points. The remaining 2 pieces are: first, the mistreatment rate in Q1, and third would be the admissions — approximately, let's say, 500 admissions that we believe were lost across a couple of weeks because of the cyber event, and those 2 are about the same magnitude. That gets you to the 50 basis points for the year. As for Q1, the shortfall was mostly the mistreatment rate. The census effect during the quarter wasn't significant, and the mistreatment rate reflected a mix of both the storms in January and February and flu.
Andrew Mok
analystUnderstood. Alright. And I believe I caught you mentioning that most of the expenses tied to the cyber attack are going to be one-time items that get recognized in Q2. Could you walk us through that a bit? Will you be adjusting those out of earnings? Or are you going to take on those costs and fold them into guidance?
Joel Ackerman
executiveI'd say there are going to be two separate categories. Some will be direct costs, which we'll treat as non-GAAP and which insurance will probably cover. As a result, those don't appear in our adjusted OI forecast. Others will be more indirect in nature, and those are going to run through the P&L, and we've factored them into our guidance.
Andrew Mok
analystUnderstood, that helps. Now regarding the oral phosphate, could you give a little additional detail about what happened during the quarter in terms of uptake and drug mix? Any further specifics you can share on that?
Javier Rodriguez
executiveYeah, thank you, Andrew. We observed that the mix tilted somewhat toward the iron base; therefore, as mentioned during the opening remarks, that essentially led us to shift the guidance toward the upper end; previously we had stated 0 to $50 million, and at this point we expect to land at the higher end of that.
Andrew Mok
analystFor the rest of the year, should we anticipate that blend shifting or developing? Or would you say that, given what you've seen in results up to now, you already have a fairly solid grasp of how that blend is shaping up?
Javier Rodriguez
executiveThis is the first quarter in which we've had this experience. However, in our conversations with physicians, the sense we get is that they are content with the blend as it stands.
Andrew Mok
analystUnderstood. All right. Perhaps one final question from my side. Could you give us some insight into how the commercial mix landed during the quarter, and what the exchange growth looked like for Q1?
Javier Rodriguez
executiveCertainly. The mix stayed the same, holding steady in the low 11% range, and open enrollment came in strong. As a result, we're carrying on a growth path much like the broader market.
Christian Porter
analystChristian Porter here, filling in for Joanna. We've got a handful of questions for you. First, I'd like to know whether you can walk us through the details of what the cyber attack did to you in terms of revenue and EBITDA, and then the effect of adding phosphate binders into the Medicare bundle.
Joel Ackerman
executiveSure. On the cyber side, to be clear, that took place in April, so Q1 saw nothing from it, and what the net effect on adjusted OI will be in Q2 is still unknown. But keep in mind, as I've said, our guidance already accounts for it. Now, what was your second question again — binders. I believe the question is how this rolls up separately into our lines: because of binders, our RPT rose by roughly $10 versus the prior quarter, and binders lifted our cost per treatment by about $8 during the quarter.
Dean Rosales
analystThis is Dean Rosales, filling in for Justin. Thanks for the fresh details regarding non-acquired treatment growth for the year. Could you share what you're expecting for RPT this year? Does that remain in the 4.5% to 5.5% range?
Joel Ackerman
executiveYes. Our guide on RPT for the year is unchanged; as Javier noted, we believe orals in the bundle will contribute somewhat more, yet it stays within the range from last quarter's guide.
Pito Chickering
analystTo revisit the treatment growth topic, could you quantify the number of patients who came in fresh during this period, plus how those individuals were being monitored in 2Q, and what the comparison looks like against the same time last year? Also, as we come out of flu season, are any shifts in mortality showing up right now?
Joel Ackerman
executiveSure. Beginning with admissions, Q1 proved to be a robust quarter for us on that front. We're aware there was substantial attention during the prior quarter. We flagged Q4 as a soft quarter for admits; and I believe plenty of people wondered whether that reflected ordinary fluctuation, which was our own suspicion, or whether it signaled the start of some pattern. The momentum during Q1 definitely backs up our theory that it was merely ordinary fluctuation. So admits were, without question, consistent with our expectations, yet Q1 was robust. Regarding mortality in Q1, it was clearly higher; our view is that this came entirely from the flu. There isn't much else to add on that point. It remains somewhat soon to determine what's occurring with mortality after the flu. As you're aware, some delay exists between a month's close and the point when we gain solid visibility into mortality. So I'm unable to tell you much regarding what took place following the flu.
Pito Chickering
analystAll right, that's reasonable. Then when we look at revenue per treatment, there are several components you mentioned, and you noted the mix held steady. Clearly, you did get a favorable lift from the phosphate. Can you put an exact figure on what phosphate contributed to RPT? Also, any further thoughts on Q1 RPT regarding managed care rate increases for this year? And how should we model co-pays and deductibles as they lap in the coming two quarters?
Javier Rodriguez
executiveYes. That's quite a few questions, so allow me to boil it down. We provided a range of about 4.5 to 5.5 RPT. Broadly speaking, in terms of buckets, half comes from growth in the core business, and the other half comes from oral. So I believe that ties together everything you asked. Does that answer it?
Pito Chickering
analystYes, that's fine. And then the final item here relates to IKC, where there's a fairly meaningful drop in patients comparing March with December. I just wanted to ask a follow-up. I believe on the prior quarter's call we discussed certain competitors being more aggressive when it comes to pricing. So what's your take on IKC patients currently receiving treatment, and how does the profitability of that stack up against what you'd anticipated?
Javier Rodriguez
executiveA few points come to mind. First, looking at it clinically, the benefit to patients is beyond dispute. Our physicians also have to alter how they go about their work and ensure they begin participating in transition of care, hospitalization, and similar areas. That requires time, as we've been telling you for a long while. On the financial side, things are unfolding the way we expected, which is that this business carries somewhat more volatility. That's why we've advised evaluating it annually. Sadly, a number of unproven newcomers have entered the space and made some inexperienced risk decisions, contracting in a rather poor and aggressive manner. What I mean is, in economic terms, we've stayed very disciplined about grasping the effect we can have on patient care, and we've stayed very disciplined with our financial modeling. So although we naturally want to earn and capture additional business, you need to do so in a way that's sustainable; and beyond that, we've also ended certain arrangements with physicians who aren't prepared to alter how they practice, since you truly must change your practice approach to succeed here.
Joel Ackerman
executivePito, I want to tack on one additional point there. A portion of the drop in lives between Q4 and Q1 also comes from how much better we've gotten at forecasting the number of lives that will be taken off attribution after the fact, according to specific rules CMS applies within the CKCC program, especially when it comes to CKD live. So this isn't an economic shift; it's really about the way we tally those lives and getting sharper at anticipating that ahead of time.
Pito Chickering
analystAll right. Then one final fast question about overseas, which seemed quite robust. I imagine there are any positives or negatives you ought to point out regarding international as you forecast it for the remaining portion of the year.
Joel Ackerman
executiveYeah. Overseas delivered a solid quarter, with plenty of positives in quite a few markets; we're pleased with the way the recent acquisition is performing; so during the prior quarter we mentioned a $50 million increase compared with a year earlier, and in Q1 we likely added another $10 million beyond that $50 million.
Albert Rice
analystPerhaps only a few items. To build on what was asked regarding Latin America: is there any news on Brazil, and perhaps wider than that, on the M&A pipeline — what are you observing? Is there anything to say about what could come in the second half of the year?
Javier Rodriguez
executiveSure, A.J. Regarding Brazil, we are quite near, even though they imposed certain limits on us that we must comply with, so we need to see that through; and sell off a pair of centers — it's never wise to speculate, but we are approaching the end. So with luck, that arrives soon. When it comes to M&A, I'd say overseas remains an intriguing market. And within the U.S., we keep going after onesie and twosies, plus whatever practice is ready to convert. So it's a lively environment out there, yet that essentially sums it up.
Albert Rice
analystJust a quick follow-up regarding the IKC matter. That $29 million loss — assuming I heard correctly — comes after shifting certain operations that would otherwise have dragged by $4 million each quarter into the core. I suppose I have 2 questions about that. It's curious that you decided to make that change; what's driving it? And next, you still believe — I realize there's quarter-to-quarter volatility — that you remain on course to reach breakeven at 27% in that business.
Joel Ackerman
executiveYes; let me clear up one point. We didn't relocate it into the core; we relocated it into other strategic initiatives. Yet I'd say the key thing is that it has zero bottom line effect on the enterprise. It's merely shifting from one business to another. This was an IT product that, when initially rolled out, was anticipated to be used mostly by the IKC business. However, as time passed, it became evident that it offered other utility within DaVita, such as in the dialysis business; so in the end, we chose to allocate that somewhat differently, yet it has no significant effect on the path to profitability. Clearly, it assists somewhat since you're simply removing cost, but within the wider context of IKC and its scale and variability, we continue to feel good about the path we were on.
Albert Rice
analystAll right. So then — if I may just ask a follow-up on that point. That $4 million loss run rate we have right now as you shift it over into this new area — does it shrink as time goes on?
Joel Ackerman
executiveNo, I wouldn't anticipate that it declines as time passes.
Albert Rice
analystAll right, and perhaps one final thing to clear up regarding your G&A—you're up roughly 3% in cost for each treatment. I realize you mentioned in the release the decreases in professional fees, and I believe it also referenced some kind of gain. Could you expand a bit further on where those were significant during the quarter? And what was happening there?
Joel Ackerman
executiveNo, I don't believe much was going on with that. I think a major shift in G&A for each treatment came about because volume declined. So there's a sizable drop in treatments from Q4 to Q1, largely caused by fewer days. That was, I believe, probably the most significant factor behind the movement in G&A per transaction.
Ryan Langston
analystSo the guidance for the entire year is staying where it was, with only a slight reduction on treatment volumes. I'm wondering whether a big chunk of that beat is coming from the phosphate binder side, or is some of it due to the stronger group of new admits you mentioned?
Joel Ackerman
executiveYeah. If I were to walk through our thinking on guidance, I'd frame it as 2 negatives affecting the quarter — or really the year. First, there's the volume decline, the 50 bps, which we lowered, and second, there are the cyber costs. Those represent headwinds for the year, and they're offset by 2 tailwinds. The first is Q1 strength, and the second is growth in the binders. When you net out those 2 headwinds against those 2 tailwinds, the result is no change.
Ryan Langston
analystAlright. I may have missed the beginning of what A.J. asked, but the release mentioned a drop in professional fees. And then, I believe, there was a gain in G&A. Could you help us size that gain — sorry again if A.J. already asked — and maybe explain what caused pro fees to fall?
Joel Ackerman
executiveSure. Those are small items, in the single-digit millions. I wouldn't worry too much about them.
Javier Rodriguez
executiveAll right. Thanks, Michelle, and thanks to everyone for what you asked. If you've been keeping up with us, you know we've run into 3 outside factors that were only temporary — supply shortages caused by a hurricane, a severe flu season, and at present a cyber incident. Even so, our clinical and financial goals keep getting met. We're eager to keep gaining momentum through what's left of this year. We'll be in touch before long. Take care.
Operator
operatorAppreciate it. That brings us to the end of today’s conference call. At this point, you’re welcome to go ahead and disconnect.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete DaVita Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to DaVita Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in DaVita Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.